Skip to main content

Table 2 ALK inhibitors in development

From: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Chemical series

Therapeutics

Development stage

Aminopyridine

PF-2341066 (crizotinib)

Phase II/III: NSCLC; phase I/II: advanced solid tumors, neuroblastoma, and ALCL

Diaminopyrimidine

CEP-28122

Preclinical

IND application expected

Structure undisclosed

AP-26113

Preclinical

IND application expected in 2011

Structure undisclosed

X-276

Preclinical

Pyridoisoquinoline

F91873 and F91874

Preclinical

Pyrrolopyrazole

PHA-E429

Preclinical

Indolocarbazole

CEP-14083 and CEP-14513

Preclinical

No further development

Pyrrolopyrimidine

GSK1838705A

Preclinical

No further development

Dianilinopyrimidine

NVP-TAE684

Preclinical

No further development

  1. NSCLC, non-small cell lung cancer; ALCL, anaplastic large cell lymphoma
  2. Reference [60, 61, 64, 65, 140150]